WHAT ABOUT U=U AND...

Adherence: The adherence of ART is essential for the success of the U=U strategy. Patients need to be educated on the importance of adherence and the consequences of non-adherence. This includes discussing the potential risks of virologic blips and the importance of maintaining a consistently undetectable viral load.

Virologic blips may occur in individuals with an undetectable viral load. These blips are transient periods of detectable viral load that are typically short-lived and not indicative of virologic failure. Patients should be educated on the importance of monitoring their viral load and understanding the implications of virologic blips.

Screening and treatment: Screening for STIs is important for individuals on U=U. STIs can be transmitted through sexual contact, and screening can help prevent their spread. Patients should be encouraged to get tested for STIs regularly.

U=U BEST PRACTICES

WHAT IS U=U?

People who achieve and maintain an undetectable HIV viral load do not sexually transmit HIV.

This scientific finding, called “Undetectable = Untransmittable,” or “U=U,” has been promoted as a health equity initiative by the Prevention Access Campaign since 2016 and has been endorsed by the CDC, the NYC DOHMH, the NYSDOH, and many other health departments and experts. U=U asserts that individuals who keep their viral load below the level of assay detection (typically HIV RNA <20 copies/mL) do not pass HIV through sex. Leading scientists recently lent their support to U=U, assessing the evidence base as “scientifically sound” [Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA 2019;321(5):451-452.]

EVIDENCE BASE SUPPORTING U=U

- The HPTN 052, PARTNER, PARTNER 2, and Opposites Attract studies followed thousands of male and heterosexual HIV-serodiscordant couples.
- There were no genetically linked HIV transmissions when the partner with HIV was taking ART and was virally suppressed (HIV RNA <200 copies/mL).
- These studies provide robust evidence that individuals do not sexually transmit HIV if they are virally suppressed or have an undetectable viral load.

NYSDOH AIDS INSTITUTE HIV CLINICAL GUIDELINES PROGRAM AUGUST 2019

U=U GUIDANCE FOR IMPLEMENTATION IN CLINICAL SETTINGS

VISIT HIVGUIDELINES.ORG TO LEARN MORE OR VIEW COMPLETE GUIDE

1/4-FOLDED GUIDE
COUNSELING INDIVIDUALS WITH HIV ABOUT U=U

Share the message that people who keep their HIV viral load at an undetectable level by consistently taking HIV medications will not pass HIV to others through sex. Sharing this message with all patients can help accomplish the following:
- Diminish stigma associated with having HIV.
- Reduce barriers to HIV testing and treatment.
- Increase interest in starting and staying on ART.
- Improve self-esteem by removing the fear of being contagious.
- Support healthy sexuality regardless of HIV status.
- Reduce sex partners’ concerns.

Encourage patients newly diagnosed with HIV and those previously diagnosed but not taking ART to immediately start (or restart) treatment.
- Explain that doing so will help them avoid damage to their body and immune system and will prevent transmission of HIV to their sex partners.
- The importance of ART should be framed primarily in terms of helping the individual with HIV maintain personal health. Prevention of transmission is a secondary, fortuitous effect of HIV self-care.
- Evidence is emerging that initiation of ART as soon as possible after diagnosis, even on the same day as diagnosis or at the first clinic visit, improves long-term outcomes, such as virologic suppression and engagement in care at 12 months.

Counsel patients to share information about the research on U=U as follows (proposed language in italics):
- In 4 recent research studies that involved thousands of couples, no one who was on HIV treatment and whose HIV was undetectable passed HIV to their HIV-negative sex partner.

Advise patients that they can share the following personal information with current or potential sex partners:
- When they last had a viral load test and if their viral load was undetectable.
- Note: Individuals should tell partners that their HIV is undetectable only if they have taken HIV medicines consistently since their last test with an undetectable viral load.

Care providers should encourage all sexually active patients and their partners, particularly those who do not use condoms consistently, to get tested regularly for bacterial STIs.
- Regular testing and prompt treatment can reduce transmission of bacterial STIs among individuals and throughout the population.
- It is also important to inform patients that common STIs may be asymptomatic.

COUNSELING COUPLES ABOUT U=U

- HIV treatment: Couples may decide that ART and an undetectable viral load for the partner with HIV provides sufficient protection against HIV transmission.
- PrEP: PrEP is a safe and effective daily pill that prevents HIV infection. The partner without HIV may decide to take PrEP if they:
  - Are unsure that their partner’s HIV viral load is undetectable, especially if their partner has only recently started ART.
  - Have more than 1 sex partner.
  - Feel more secure with the added perception of protection provided by PrEP. (See the NYSDOH AI guideline PrEP to Prevent HIV Infection > Non–Occupational Exposure Risk for more information.)
- Condom use: Condoms protect against other STIs, such as gonorrhea, chlamydia, and syphilis, and help prevent pregnancy.
- Counsel patients to find a prevention strategy that works for them:
  - If an individual who does not have HIV is unsure if their partner has an undetectable level of virus or is anxious about acquiring HIV, care providers should encourage that person to choose a prevention strategy that works for them, whether that is use of PrEP, emergency PEP, condoms, or a combination of these strategies.
  - Care providers should emphasize that no one should ever be compelled to have sex without condoms.

GLOSSARY

Viral load suppression: When a person with HIV has a measured quantitative HIV RNA level <200 copies/mL of blood.

Undetectable viral load: When an HIV viral load is below the level of detection on a specific assay, typically HIV RNA <20 copies/mL but as high as 50 copies/mL.

DURABLY UNDETECTABLE: When a person has maintained an undetectable viral load for at least 6 months—indicating that their HIV is at a stable, undetectable level and that they will not pass HIV through sex if they continue to adhere to treatment.

Untransmittable: The finding—established by various clinical trials and observational studies—that people who maintain an undetectable viral load have so little HIV in their blood and other secretions that they have “effectively no risk” of passing HIV to others through sex.

WHAT TO SAY TO PATIENTS ABOUT U=U (PROPOSED SCRIPT)

- Keeping your HIV undetectable helps you live a long and healthy life.
- To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral medicines as prescribed.
- It may take up to 6 months of taking HIV treatment medicines to bring your HIV down to an undetectable level.
- If your HIV is undetectable and you are taking your medications as prescribed, you can be sure you will not pass HIV through sex.
- People who keep their HIV at an undetectable level will not pass HIV to others through sex.
- If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 weeks, and you may pass HIV to your sex partners.
- Keeping your HIV at an undetectable level helps you safely conceive a child with your partner.